Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
2 Months : From Nov 2019 to Jan 2020
By Stephen Nakrosis
The Janssen Pharmaceutical Cos. of Johnson & Johnson said Friday the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for JNJ-68284528, an investigational therapy to treat certain myeloma patients.
Janssen said the designation was supported by results from its Phase 1b/2 CARTITUDE-1 study, a multicenter clinical trial evaluating the safety and efficacy of JNJ-4528 currently active in the U.S.
"The primary objective of the Phase 1b portion of the study is to characterize the safety of JNJ-4528 and confirm the dose for future clinical trials," the company said.
--Write to Stephen Nakrosis at firstname.lastname@example.org
(END) Dow Jones Newswires
December 06, 2019 16:48 ET (21:48 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.